(MedPage Today) — At the San Antonio Breast Cancer Symposium, investigators reported phase III results showing that the oral selective estrogen-receptor degrader (SERD) giredestrant significantly reduced recurrence risk compared with standard…
Source link : https://www.medpagetoday.com/meetingcoverage/sabcs-vp-earlybrca/119132
Author :
Publish date : 2025-12-22 17:28:00
Copyright for syndicated content belongs to the linked Source.
